Hoth Therapeutics, Inc. (HOTH)

Market Cap	5.20M
Revenue (ttm)	n/a
Net Income (ttm)	-7.85M
Shares Out	4.40M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,520
Open	1.190
Previous Close	1.230
Day's Range	1.170 - 1.230
52-Week Range	0.990 - 4.300
Beta	0.61
Analysts	Strong Buy
Price Target	7.50 (+535.59%)
Earnings Date	May 13, 2024

About HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 15, 2019
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: HOTH

Analyst Forecast

According to 5 analysts, the average rating for HOTH stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 535.59% from the latest price.

Price Target

$7.5

(535.59% upside)

Analyst Consensus: Strong Buy